Our partner is a biotechnology company pioneering bioengineered organ technology with the goal of eliminating the organ transplant waiting list. Using a proprietary perfusion decellularization and recellularization platform, the company is developing fully implantable human organs derived from donor organs.

This critical hire led CMC strategy and execution to advance pipeline programs through key development milestones. Oversaw process development, tech transfer, and GMP manufacturing while ensuring compliance with regulatory requirements. Collaborated cross-functionally to align CMC activities with clinical, regulatory, and commercial objectives.